Navigation Links
Pharmacopeia Announces Management Team Changes
Date:2/28/2008

ee years and, along the way, have assembled a solid group of scientists in both discovery and development as evidenced by today's announcements regarding Rene and David."

Dr. Belder has served as Vice President, Clinical and Regulatory Affairs since November 2006. He joined Pharmacopeia from Bristol-Myers Squibb, where during his 19-year tenure he served as a therapeutic expert in the areas of cardiovascular and metabolic diseases, and gained extensive global experience in leading clinical development programs and working with thought leaders in various clinical areas. His work included all phases of clinical development, as well as extensive interaction with the Food and Drug Administration, including leadership of the team responsible for the NDA for muraglitazar, a dual PPAR agonist.

Dr. Kimball has served as Senior Vice President, Chemistry and Preclinical Chemical Development since September 2007. Previously, he served as Vice President, Medicinal Chemistry at Lexicon Pharmaceuticals, where he successfully directed that company's chemistry effort to discover drug candidates in multiple therapeutic areas, several of which have entered clinical development. Prior to that, Dr. Kimball spent nearly 20 years at Bristol-Myers Squibb Pharmaceutical Research Institute. In various research roles at BMS, he oversaw innovative drug discovery and development projects in the areas of cardiovascular disease and oncology.

"Since joining Pharmacopeia, Rene and David have both made significant contributions to the success of the company's R&D," said Dr. Browne. "Both of these promotions are well-deserved and Pharmacopeia is fortunate to have these talented individuals playing critical roles in charting the scientific course for the company."

ABOUT PHARMACOPEIA

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference
2. Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Reminder Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
4. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
5. West Pharmaceutical Services Announces Quarterly Dividend
6. Beijing 2008 Olympic Games Vegetable Supplier Considering Kiwa as a Supplier of Bio-Fertilizers & Kiwa Announces CEO Interview with WallSt.net
7. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
8. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
9. DARA BioSciences, Inc. Announces Appointment of New Director to Board
10. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
11. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... SOUTH SAN FRANCISCO, Calif. , May 20, ... VCYT ) today presented preliminary data demonstrating ... help distinguish idiopathic pulmonary fibrosis (IPF) from other ... bronchoscopy. The findings suggest the classifier,s potential to ... expensive surgery to resolve ambiguity in IPF diagnosis ...
(Date:5/20/2015)... , May 19, 2015 Research and Markets ... the "Global Cell Therapy Market Outlook 2020 " ... cell therapy in tissue and regenerative medicine is expected ... other options which could help in the growth of ... segment but they are unable to form new tissue ...
(Date:5/20/2015)... DENVER , May 20, 2015  Health ... connecting short-staffed healthcare organizations with job seekers looking ... SHIFT , a new mobile and online tool ... the healthcare industry. SHIFT enables employers ... locum tenens, travel nursing, per diem and other ...
(Date:5/20/2015)... , May 20, 2015  Haemonetics Corporation (NYSE: ... President & CEO, will present at The Jefferies 2015 ... on June 1 st , 2015 at 8:30am ... Mr. Concannon,s presentation live via webcast at: ... (NYSE: HAE ) is a global healthcare company ...
Breaking Biology Technology:Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
... , , , ... Choose Shrimp Alkaline Phosphatase,for Easier Heat Inactivation , ... , , Simplify dephosphorylation of 5′ ends ... Shrimp Alkaline Phosphatase completely,and irreversibly by heating at 65 C for only 15 ...
... , , ... , Polymerase chain reaction (PCR) setup typically requires,thawing of ... individual reaction tubes. ,The various handling steps, , , ... , bear the risk of contaminating the amplification,reaction and , ...
... , , Product Literature Center Articles , , ... , , ... Patterns with Improved Tools for Target Amplification , , , ... FastStart Taq DNA Polymerase and the Novel FastStart High Fidelity PCR System , ...
Cached Biology Technology:Reduce Errors and Save Time When Setting Up PCRs 2Roche Diagnostics Corporation 2Roche Diagnostics Corporation 3Roche Diagnostics Corporation 4Roche Diagnostics Corporation 5
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
(Date:4/27/2015)... Fla. , Apr. 27, 2015 Profile ... access control and security systems is pleased to announce ... company as a consultant and member of its scientific ... is widely known as a thought leader in technology-enhanced ... Learning Technology Group, and has published studies and books ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... Researchers at Georgetown University Medical Center have discovered ... on genes that can push stem cells embedded in a ... build blood vessels to link up to the body,s blood ... published in the July 16 online issue of PLoS ...
... Although sickle cell disease is a single-gene disorder, its ... July 14 by the Proceedings of the National ... and the Dana Farber Cancer Institute (DFCI), in collaboration ... five gene variants that could potentially be helpful in ...
... 15, 2008 A new book from the Soil Science Society of ... living world of soil. Soil! Get the Inside Scoop explores how ... the air we breathe, the water we drink, the houses we ... healthy plants and food production. Written for children age 9 to ...
Cached Biology News:Vitamin A pushes breast cancer to form blood vessel cells 2Vitamin A pushes breast cancer to form blood vessel cells 3Gaining ground on sickle cell disease 2Gaining ground on sickle cell disease 3
... (OSM) is a pleiotropic cytokine produced by ... cells. OSM inhibits the growth of some ... smooth muscle and Kaposis sarcoma cell proliferation, ... density lipoprotein receptor expression on hepatoma cells. ...
... trinor Prostaglandin F2α isopropyl ester (15(R)-17-phenyl ... latanoprost-related isomer containing both a double ... (β) hydroxyl group at C-15. Similar ... ester is a potential impurity in ...
ACS Reagent Grade C 19 H 14 O 5 S Formula Weight: 354.38 PRODUCT SPECIFICATIONS Form: Rust/red crystalline powder Clarity of Solution: Passes test Visual Transition Interval: pH 6.8 - Yellow pH 8.2...
... Mouse Anti Nop1p/Fibrillarin (monoclonal) ... nucleolar protein of bakers yeast, Saccharomyces ... is essential for yeast viability and ... human homologue of Nop1p is fibrillarin ...
Biology Products: